Skip Navigation



Annals of Oncology Advance Access published online on January 27, 2005
Annals of Oncology, doi:10.1093/annonc/mdi085
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/3/389    most recent
mdi085v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Arriagada, R.
Right arrow Articles by Tursz, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arriagada, R.
Right arrow Articles by Tursz, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received July 22, 2004
Revised October 18, 2004
Accepted October 25, 2004

Original article

Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy

R. Arriagada 1*, M. G. Lê 2, M. Spielmann 2, L. Mauriac 3, J. Bonneterre 4, M. Namer 5, T. Delozier 6, C. Hill 2, and T. Tursz 1

1 Institut Gustave-Roussy, Villejuif, France; Faculté de Médecine, Université de Paris XI, Paris, France
2 Institut Gustave-Roussy, Villejuif, France
3 Institut Bergonié, Bordeaux, France
4 Centre Oscar Lambret, Lille, France
5 Centre Antoine Lacassagne, Nice, France
6 Centre François Baclesse, Caen, France

* To whom correspondence should be addressed.
R. Arriagada, E-mail: arriagada{at}igr.fr


  Abstract

Purpose: The aim of this multicenter trial was to evaluate the role of ovarian suppression in patients with early breast cancer previously treated with local surgery and adjuvant chemotherapy.

Patients and methods: Nine hundred and twenty-six premenopausal patients with completely resected breast cancer and either axillary node involvement or histological grade 2 or 3 tumors were randomized after surgery to adjuvant chemotherapy alone (control arm) or adjuvant chemotherapy plus ovarian suppression (ovarian suppression arm). Ovarian suppression was obtained by either radiation-induced ovarian ablation or triptorelin for 3 years. The analyses were performed with Cox models stratified by center.

Results: Median follow-up was 9.5 years. Mean age was 43 years. Ninety per cent of patients had histologically proven positive axillary nodes, 63% positive hormonal receptors and 77% had received an anthracycline-based chemotherapy regimen. Ovarian suppression was by radiation-induced ovarian ablation (45% of patients) or with triptorelin (48%). At the time of randomization, all patients had regular menses or their follicle-stimulating hormone and estradiol levels indicated a premenopausal status. The 10-year disease-free survival rates were 49% [95% confidence interval (CI) 44% to 54%] in both arms (P=0.51). The 10-year overall survival rates were 66% (95% CI 61% to 70%) for the ovarian suppression arm and 68% (95% CI 63% to 73%) for the control arm (P=0.19). There were no variations in the treatment effect according to age, hormonal receptor status or ovarian suppression modality. However, in patients <40 years of age and with estrogen receptor-positive tumors, ovarian suppression significantly decreased the risk of recurrence (P=0.01).

Conclusions: The results of this trial, after at least 10 years of follow-up, do not favor the use of ovarian suppression after adjuvant chemotherapy. The potential beneficial effect in younger women with hormono-dependent tumors should be further assessed.

Keywords: early breast cancer; premenopause; ovarian suppression; randomized trial.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
R. Arriagada
International expert consensus on radiotherapy of early breast cancer
Ann. Onc., December 1, 2007; 18(12): 2043 - 2044.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, S. De Placido, C. K. Osborne, and R. Schiff
Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy
J Natl Cancer Inst, May 2, 2007; 99(9): 694 - 705.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. C. Wolff and N. E. Davidson
Still Waiting After 110 Years: The Optimal Use of Ovarian Ablation As Adjuvant Therapy for Breast Cancer
J. Clin. Oncol., November 1, 2006; 24(31): 4949 - 4951.
[Full Text] [PDF]

Home page
 Ann OncolHome page
L. Del Mastro, T. Catzeddu, L. Boni, C. Bell, M. R. Sertoli, C. Bighin, M. Clavarezza, D. Testa, and M. Venturini
Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients
Ann. Onc., January 1, 2006; 17(1): 74 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and and Panel Members
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005
Ann. Onc., October 1, 2005; 16(10): 1569 - 1583.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.